高盛发表报告指，默沙东次季盈利胜预期，但财务和前景的更新较为复杂。在最受关注的增长动力方面，注意到加卫苗(Gardasil)专营权在中国和美国持续存在不确定性。高盛对其目标价由99美元下调至94美元，以反映模型更新，以及因加卫苗的持续不确定性和近期催化路径而调降的估值倍数，评级“买入”。该行指，好消息是公司主要新产品周期Winrevair的表现仍然完好，且管理层重申乐观预期，来自潜在的适应症扩展以及HYPERION试验的详细数据，两者都预计在今年稍后时间进行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.